Grifols, S.A. (NASDAQ:GRFS) Short Interest Down 9.5% in August

Grifols, S.A. (NASDAQ:GRFS) was the recipient of a large drop in short interest in August. As of August 31st, there was short interest totalling 5,530,000 shares, a drop of 9.5% from the August 15th total of 6,110,000 shares. Based on an average daily volume of 1,740,000 shares, the days-to-cover ratio is currently 3.2 days. Currently, 2.2% of the company’s shares are short sold.

Institutional Trading of Grifols

Institutional investors have recently made changes to their positions in the stock. Brandes Investment Partners LP lifted its position in Grifols by 22.2% in the 4th quarter. Brandes Investment Partners LP now owns 13,516,011 shares of the biotechnology company’s stock worth $156,245,000 after buying an additional 2,454,730 shares in the last quarter. Norges Bank acquired a new stake in Grifols during the fourth quarter valued at $26,137,000. Armistice Capital LLC grew its stake in Grifols by 18.7% in the second quarter. Armistice Capital LLC now owns 7,892,000 shares of the biotechnology company’s stock valued at $49,759,000 after purchasing an additional 1,244,000 shares in the last quarter. Capital World Investors increased its position in Grifols by 4.9% in the 1st quarter. Capital World Investors now owns 20,749,225 shares of the biotechnology company’s stock worth $138,605,000 after purchasing an additional 961,700 shares during the last quarter. Finally, Highland Peak Capital LLC purchased a new stake in shares of Grifols during the 2nd quarter worth about $5,991,000.

Grifols Stock Performance

Shares of GRFS traded down $0.34 during midday trading on Tuesday, hitting $8.90. The stock had a trading volume of 815,654 shares, compared to its average volume of 2,133,314. Grifols has a fifty-two week low of $5.30 and a fifty-two week high of $12.15. The company has a debt-to-equity ratio of 1.06, a quick ratio of 0.80 and a current ratio of 1.68. The business has a 50-day simple moving average of $8.14 and a two-hundred day simple moving average of $7.28.

Grifols (NASDAQ:GRFS) last issued its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.21). The business had revenue of $1.96 billion for the quarter. Grifols had a net margin of 0.90% and a return on equity of 1.73%. Equities analysts expect that Grifols will post 0.79 earnings per share for the current fiscal year.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.